NASDAQ:GERN - Nasdaq - US3741631036 - Common Stock - Currency: USD
1.27
+0.03 (+2.42%)
The current stock price of GERN is 1.27 USD. In the past month the price decreased by -27.43%. In the past year, price decreased by -65.58%.
Symbol | Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABBV | ABBVIE INC | 17.09 | 306.02B | ||
AMGN | AMGEN INC | 13.99 | 149.08B | ||
GILD | GILEAD SCIENCES INC | 22.68 | 130.32B | ||
VRTX | VERTEX PHARMACEUTICALS INC | 1686.55 | 125.74B | ||
REGN | REGENERON PHARMACEUTICALS | 12.34 | 61.56B | ||
ARGX | ARGENX SE - ADR | 318.82 | 36.23B | ||
ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 30.51B | ||
ONC | BEIGENE LTD-ADR | N/A | 24.88B | ||
BNTX | BIONTECH SE-ADR | N/A | 23.74B | ||
NTRA | NATERA INC | N/A | 20.02B | ||
SMMT | SUMMIT THERAPEUTICS INC | N/A | 18.15B | ||
BIIB | BIOGEN INC | 7.2 | 17.36B |
Geron Corp. operates as a biotechnology company. The company is headquartered in Foster City, California and currently employs 229 full-time employees. The firm is engaged in the development of therapeutic products for oncology. Its lead indication for imetelstat is in Low or Intermediate-1 risk myelodysplastic syndromes. The company is developing imetelstat for the treatment of several myeloid hematologic malignancies, including a Phase 3 clinical trial, named IMpactMF, in relapsed/refractory myelofibrosis (MF) with overall survival as the primary endpoint, that is enrolling patients. The company is also conducting a Phase 1 combination therapy clinical trial, named IMproveMF, in first-line Intermediate-1, Intermediate-2 or High-Risk myelofibrosis, or frontline MF, that is enrolling patients and imetelstat is being studied in an investigator-led Phase 2 clinical trial, named IMpress, in Intermediate-2 or High-Risk myelodysplastic syndromes and acute myeloid leukemia.
GERON CORP
919 East Hillsdale Boulevard, Suite 250
Foster City CALIFORNIA 94404 US
CEO: John A. Scarlett
Employees: 229
Company Website: https://www.geron.com/
Investor Relations: https://ir.geron.com/
Phone: 16504737700
The current stock price of GERN is 1.27 USD. The price increased by 2.42% in the last trading session.
The exchange symbol of GERON CORP is GERN and it is listed on the Nasdaq exchange.
GERN stock is listed on the Nasdaq exchange.
15 analysts have analysed GERN and the average price target is 4.59 USD. This implies a price increase of 261.42% is expected in the next year compared to the current price of 1.27. Check the GERON CORP stock analysts ratings, price target forecast and up-and down grades for more detailed information.
GERON CORP (GERN) has a market capitalization of 808.88M USD. This makes GERN a Small Cap stock.
GERON CORP (GERN) currently has 229 employees.
GERON CORP (GERN) has a resistance level at 1.74. Check the full technical report for a detailed analysis of GERN support and resistance levels.
The Revenue of GERON CORP (GERN) is expected to grow by 213.35% in the next year. Check the estimates tab for more information on the GERN EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
GERN does not pay a dividend.
GERON CORP (GERN) will report earnings on 2025-05-07, before the market open.
GERON CORP (GERN) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.27).
The outstanding short interest for GERON CORP (GERN) is 9.23% of its float. Check the ownership tab for more information on the GERN short interest.
ChartMill assigns a fundamental rating of 3 / 10 to GERN. While GERN seems to be doing ok healthwise, there are quite some concerns on its profitability.
Over the last trailing twelve months GERN reported a non-GAAP Earnings per Share(EPS) of -0.27. The EPS increased by 18.18% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -29.4% | ||
ROE | -62.28% | ||
Debt/Equity | 0.42 |
ChartMill assigns a Buy % Consensus number of 83% to GERN. The Buy consensus is the average rating of analysts ratings from 15 analysts.
For the next year, analysts expect an EPS growth of 60.54% and a revenue growth 213.35% for GERN